Flamma Opens New cGMP Plant in China

This milestone aligns with the company’s broader strategy to invest significantly across its global network.

“Flamma has been present in the Chinese market for over 30 years. Initially, we focused on sourcing key raw materials directly to secure the supply chain. We then established our own R&D laboratory in China, which ultimately led to the formation of Flamma Honkai in Dalian in 2012. We are extremely proud of what we’ve accomplished over the past 17 years of operations in Dalian. With Honkai being a fully owned and run subsidiary, we’ve been able to combine Flamma’s core values and expertise with the efficiency of the Honkai management team, leading to a 30-fold increase in turnover, Chinese FDA approval, and significant market growth,” says GianPaolo Negrisoli, President and CEO.

“As we inaugurate this major site in Dalian, we also reaffirm our roots,” adds GianMarco Negrisoli, Executive Director – Corporate Development. “This global expansion complements the substantial investments we are making in Italy, including significant facility upgrades, capacity increases, and continued recruitment of high caliber talent. Flamma plans to reinvest $200 million worldwide over the next five years to grow our manufacturing capacity, technology and capabilities, reinforcing the synergy between its Italian heritage and global outlook.”